Barclays
RBOT

Barclays’s Vicarious Surgical RBOT Stock Holding History

Barclays’s Portfolio RBOT Stock Details RBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-401
Closed -$2.35K – 5437
2024
Q2 		$2.35K Sell
401
-2,154
-84% -$19.3K ﹤0.01% 4630
2024
Q1 		$23.1K Sell
2,555
-2,121
-45% -$25.3K ﹤0.01% 4740
2023
Q4 		$51.4K Buy
4,676
+4,175
+833% +$46.5K ﹤0.01% 4772
2023
Q3 		$8.88K Buy
501
+34
+7% +$1.24K ﹤0.01% 4321
2023
Q2 		$25.6K Sell
467
-469
-50% -$29.9K ﹤0.01% 4085
2023
Q1 		$63.8K Buy
936
+441
+89% +$34.3K ﹤0.01% 4365
2022
Q4 		$30K Buy
495
+418
+543% +$38.9K ﹤0.01% 4722
2022
Q3 		$8K Sell
77
-14
-15% -$1.63K ﹤0.01% 4395
2022
Q2 		$8K Buy
91
+89
+4,450% +$10.9K ﹤0.01% 4699
2022
Q1 		$0 Buy
+2
New +$372 ﹤0.01% 5490

Other funds holding RBOT

VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
DP
DDD Partners Bellevue, Washington $1.45B AUM 9.14% 1-Year Est. Return
MAMHA
MY.Alpha Management HK Advisors Hong Kong $246M AUM 73.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AMH
Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return

Barclays's RBOT Position: Q3 2024 in Review

Barclays sold out of Vicarious Surgical (RBOT) in Q3 2024, closing a stake of 401 shares — an estimated $2.35K sold.

Barclays first reported a position in RBOT in Q1 2022 and held it in 10 quarters. The position peaked at $63.8K in Q1 2023. 34 funds tracked by Wall St. Rank hold RBOT as of Q3 2024.

  • Barclays reported no remaining Vicarious Surgical position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 401 Vicarious Surgical shares in Q3 2024, an estimated $2.35K.
  • Barclays first reported a position in Vicarious Surgical in Q1 2022 and held it in 10 quarters.
  • Barclays's Vicarious Surgical position peaked at $63.8K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Vicarious Surgical as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.